GBI Research, May 2011, Pages: 69
studies of successful generic growth strategies.
- Competitive profiling of leading companies. The key companies studied in this report are Teva, Sandoz, Hospira, Watson, Mylan, Perrigo, STADA, DRL, Par
Datamonitor, April 2010, Pages: 24
The Sandoz International GmbH - SWOT Analysis company profile is the essential source for top-level company data and information. Sandoz International GmbH - SWOT Analysis examines the company’s key
Datamonitor, Sep 2010, Pages: 24
The Sandoz International GmbH - SWOT Analysis company profile is the essential source for top-level company data and information. Sandoz International GmbH - SWOT Analysis examines the company’s key
Espicom Business Intelligence Ltd, March 2010, Pages: 128
With high-profile inhalable drugs coming off patent, the prospects for the generic sector should be good - but only if companies can overcome production, regulatory and litigation hurdles
Yano Research Institute Ltd., Dec 2010, Pages: 187
Generic Drug Market in Japan 2010 is a comprehensive resource book on the current generic drug market in Japan. It provides you with a full picture of the market by covering market size
Yano Research Institute Ltd., Dec 2010, Pages: 187
Generic Drug Market in Japan 2010 is a comprehensive resource book on the current generic drug market in Japan. It provides you with a full picture of the market by covering market size
Global Industry Analysts, Inc., Feb 2011, Pages: 349
for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets.
The report profiles 55 companies including many key and niche players such as
- Biocon Ltd. (India
Frost & Sullivan, Aug 2008, Pages: 76
on Bio-generics
---Product Off-label and Investigational Uses
---Debate on Off-label Use of Growth Hormone
--Market Trends
---Market Trends
---Industry Challenges
---Market Drivers
CYGNUS Business Consulting & Research, Aug 2011, Pages: 153
Players - their business and financial profile, key strategies, R&D pipeline and outlook for the company.
- Amount & Area of R&D spend of major generic companies
- Regulations governing generics, Key patent
Research Facts Ltd, Oct 2009, Pages: 120
of certain diseases and the rise in prices for originator pharmaceuticals are creating a critical need for more generic medicines.
This report profiles the Top 60 European generic pharmaceutical manufacturers
Espicom Business Intelligence Ltd, April 2006, Pages: 192
in Latin America ...
Each market profile typically provides
KEY DATA
EXECUTIVE SUMMARY
GENERIC REGULATORY ENVIRONMENT
Generic Regulation
Generic Prescribing
Bioequivalence
Patent Protection & Intellectual Property
Global Industry Analysts, Inc., July 2009, Pages: 1810
Receives FDA Approval for Banzel™ (Rufinamide) II-146
Progenics Receives FDA Approval for RELISTOR II-146
J&J Receives Approval for Anti-HIV Medication ‘Intelence’ II-146
Sandoz Launches Generic Fluoxetine
VOI Consulting, Inc., March 2009, Pages: 500
The industry's most comprehensive source on the generic durg industry in the US.
Coverage includes sections:
- Products / Market
- Regulatory
- Top company profiles
TOPICS COVERED INCLUDE
IMS Health, July 2011, Pages: 69
Therapeutic Classes (Level 3) 2008
Figure 8-22: Leading 15 Therapeutic Class Profiles
Figure 23: Leading 40 Products
Figure 24: Leading 40 New Products
Figure 25: Leading 15 Product Forms
Appendices
IMS Health, July 2011, Pages: 73
Therapeutic Classes (Level 3) 2008
Figure 8-22: Leading 15 Therapeutic Class Profiles
Figure 23: Leading 40 Products
Figure 24: Leading 40 New Products
Figure 25: Leading 15 Product Forms
Appendices
Espicom Business Intelligence Ltd, Dec 2009, Pages: 318
will become susceptible to generic competition either following patent expiry, or as a result of patent infringement litigation going against Teva. The US patents expire in 2014. In the meantime, Sandoz
Fuji-Keizai USA, Inc., March 2010, Pages: 267
by Segment in Millions, 2008 - 2013
5.3.3 Issues, Sales Drivers and Restraints
6. Activities of Generic and Biogeneric Drug Makers
Common Research Item
- Profile
Contact
- URL
- Sales 2008
- Generic
Fuji-Keizai USA, Inc., Jan 2010, Pages: 269
by Segment in Millions, 2008 - 2013
5.3.3 Issues, Sales Drivers and Restraints
6. Activities of Generic and Biogeneric Drug Makers
Common Research Item
- Profile
Contact
- URL
- Sales 2008
- Generic
